Comera Life Sciences (NASDAQ:CMRA) CEO Jeff Hackman joins Natalie Stoberman from the Proactive studio to share new updates about the company's recent private placement.
Comera Life Sciences applies formulation science and technology to transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The goal is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen.